Exeliom Biosciences
France - DijonBiotechnology
Focus: Exeliom Biosciences is a French biotech focused on gut microbiome modifiers for gastroenterology and adjacent indications. The company is in early-stage development with a single clinical-stage program (EXL01) in Phase 1/2 across three indications.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Exeliom Biosciences
AI assessmentNot HiringNo open roles listed right now. Follow Exeliom Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
EXL01
Crohn DiseaseClinical Trials (1)
NCT05542355EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease
Phase 1Help build intelligence for Exeliom Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.